Corporate Demo
Description
Vocal Characteristics
Language
EnglishVoice Age
Middle Aged (35-54)Accents
British (General) British (Received Pronunciation - RP, BBC)Transcript
Note: Transcripts are generated using speech recognition software and may contain errors.
I. Next is a women's healthcare and diagnostic company based in Singapore. We operate two main business lines in women's and reproductive health one. Women's health, innovation in prenatal testing and ovarian cancer. Diagnostic to Molecular Diagnostic Laboratory With our products, we work to give women the assurance and peace of mind that comes from groundbreaking science and technology by providing safer earlier on more accurate diagnostic results. To improve health outcomes, our founders are key opinion leaders in the fields of foetal maternal on women's health. Having worked at the National University of Singapore, they shaped clinical and academic medicine in the fields of obstetrics and gynaecology on molecular diagnostics. Today, Hynix has achieved these key milestones. One i g laboratory, a clinical next generation sequencing lab in Singapore. Two oh versus the world's first point of care diagnostic kit for the detection of ovarian cancer. Three. A strong I P portfolio for commercial distribution agreements throughout Asia. We continue to invest in R and D to develop and bring progressive technologies in our mission to help women make informed decisions about their health. Tomorrow's world will be one where we can identify disease long before a person ever has symptoms. This is the world of precision medicine and Hynix is at the forefront of it. We want to deliver precision medicine solutions to meet the demands of women's and foetal health. Introducing Project Lexi I nexus revolutionary technology which can isolate foetal cells in maternal blood. This has long been held as the holy Grail of prenatal diagnostics. While today is noninvasive prenatal test comm screen up to 14 diseases. My neck's revolutionary N I. P d will allow unprecedented on definitive diagnosis of over 4000 diseases in the foetus with an accuracy of 100%. When successfully isolated, Phoenix will be able to unravel the genetic code and identify the complete foetal blueprint. This will impact precision medicine like never before, and enable timely medical and surgical treatments before and after birth. I Necks has developed a proof of concept for Project. Lexi on the test is anticipated to be commercially available in 2021. For a patient with a very in cancer, early diagnosis can be challenging. Disease identification has traditionally been identified late via biopsy, resulting in poor prognosis for the patient. Liquid biopsies are a diagnostic test designed to replace invasive biopsies or imaging procedures requiring only a blood sample and not tissue. A blood test could provide a less expensive on less invasive way to monitor patients throughout treatment, helping women avoid additional surgeries whilst helping clinicians make better decisions on patient management. The science is based on Micro R N A, which provide new and valuable information to doctors on this discovery, has substantial implications for the detection off. A vary in cancer. I next is developing a liquid biopsy to diagnose early and late stage ovarian cancer on the test is anticipated to be commercially ready by 2021. With our blood based seen attest and existing overseas kit, we will reinforce our commitment to improving diagnostics in the ovarian cancer space.